Troluce Capital Advisors LLC Has $13.93 Million Stake in GH Research PLC $GHRS

Troluce Capital Advisors LLC grew its stake in GH Research PLC (NASDAQ:GHRS) by 165.4% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 990,472 shares of the company’s stock after purchasing an additional 617,260 shares during the period. GH Research comprises about 0.9% of Troluce Capital Advisors LLC’s investment portfolio, making the stock its 29th biggest position. Troluce Capital Advisors LLC’s holdings in GH Research were worth $13,926,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also bought and sold shares of GHRS. Renaissance Technologies LLC acquired a new stake in GH Research in the 1st quarter valued at about $290,000. North Star Investment Management Corp. bought a new stake in GH Research during the 1st quarter worth approximately $31,000. Avoro Capital Advisors LLC bought a new position in GH Research during the 4th quarter worth about $22,860,000. XTX Topco Ltd bought a new stake in GH Research in the 4th quarter valued at approximately $564,000. Finally, Virtus Investment Advisers LLC lifted its position in shares of GH Research by 130.1% in the fourth quarter. Virtus Investment Advisers LLC now owns 20,408 shares of the company’s stock worth $259,000 after purchasing an additional 11,539 shares in the last quarter. Institutional investors and hedge funds own 56.90% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on GHRS. Weiss Ratings restated a “sell (d-)” rating on shares of GH Research in a report on Friday, July 17th. HC Wainwright dropped their price objective on shares of GH Research from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. Citigroup reissued an “outperform” rating on shares of GH Research in a report on Friday, May 15th. Zacks Research downgraded shares of GH Research from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 15th. Finally, Cantor Fitzgerald raised their price target on GH Research from $25.00 to $35.00 and gave the stock an “overweight” rating in a research report on Friday, May 15th. Nine equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, GH Research currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.38.

GH Research Stock Performance

Shares of NASDAQ:GHRS opened at $27.28 on Monday. GH Research PLC has a 52-week low of $11.32 and a 52-week high of $31.00. The company has a market capitalization of $1.87 billion, a PE ratio of -29.65 and a beta of 1.28. The company has a fifty day moving average of $24.43 and a 200-day moving average of $19.30.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). On average, equities analysts forecast that GH Research PLC will post -1.46 EPS for the current fiscal year.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.